obesity-995x60.png
FEATURED ARTICLES
Rural Patients Are Ready For Trials. Are Sponsors?
Rural America has millions of potential trial participants, but few sites to serve them. Rovia's CEO explains why finding and keeping the right principal investigators may be the real challenge, and what sponsors need to prove next.
-
Ophthalmic Assessment Requirements For Drugs With Ocular Toxicity Risk
No eye care staff at your sites? See what FDA labels for drugs with known eye toxicity require, and how to keep slit lamp, retinal and eye pressure exams on the dosing schedule.
-
Standardizing OCT Scans Across Multi-Site Clinical Trials
Who should run OCT scans at each trial site? Compare three delivery models and the controls that keep retinal images consistent from first scan to last.
-
Why Radioligand Therapy Studies Look Nothing Like Standard Oncology Phase 1s
Radioligand therapy (RLT) trials demand specialization. Affibody's Fredrik Frejd explains how they differ in design and execution from standard oncology Phase 1 studies.